相关实验视频
Updated: Jul 24, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
959
用提罗菲班治疗后的严重急性血小板缺血症:一个病例系列方法
Gian-Manuel Jiménez-Rodríguez1, Patricia Carmona-Levario1, José-Alberto Ayón-Martínez1
1Interventional Cardiology Department, National Institute of Cardiology Ignacio Chávez Mexico City, Mexico.
Interventional cardiology (London, England)
|July 3, 2023
概括
一名因急性冠状动脉综合征而接受治疗的患者发生了严重的血小板缩. 迅速暂停提洛菲班输液解决了这种情况,强调需要区分药物诱导的血小板缺血症.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖蛋白IIb/IIIa抑制剂是急性冠状动脉综合征的重要辅助疗法.
- 已知不良反应是出血和血栓塞缩,发生在1-2%的患者中.
研究的目的:
- 在ST升高心肌梗塞患者中报告可能与蒂罗菲班相关的严重血小板缩病例.
- 强调区分药物诱导的血小板缺血和其他原因的重要性.
主要方法:
- 一名66岁的女性患者患有ST升高MI,接受了血栓消毒疗法,随后进行皮肤冠状动脉干预.
- 该患者接受了非分离的肝素和铁洛菲班输液治疗.
- 干预后对临床表现和实验室值进行了监测.
主要成果:
- 经皮肤冠状动脉干预和蒂罗菲班输液后发生的严重血小板缺血,出血和牙周流动.
- 推罗菲班输液被暂停,导致出血并发症的解决.
- 在随访期间没有观察到严重出血或随后的出血并发症.
结论:
- 在患有急性冠状动脉综合征和血小板衰竭的患者中,应考虑药物诱导的血小板衰竭,特别是来自蒂罗菲班.
- 早期识别和停止违规代理对患者管理至关重要.
- 需要高的怀疑指数来区分氨酸诱导的血栓塞缩症与其他药物诱导的原因.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
13
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
13
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
566
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
566

